Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Cardiol ; 121(8): 897-902, 2018 04 15.
Article in English | MEDLINE | ID: mdl-29452691

ABSTRACT

The characteristics and predictors of long-term recurrent ischemic cardiovascular events (RICEs) after myocardial infarction with ST-segment elevation (STEMI) have not yet been clarified. We aimed to characterize the 10-year incidence, types, and predictors of RICE. We obtained 10-year follow-up of STEMI survivors at 17 Quebec hospitals in Canada (the AMI-QUEBEC Study) in 2003. There were 858 patients; mean age was 60 years and 73% were male. The majority of patients receive reperfusion therapy; 53.3% and 39.2% of patients received primary percutaneous coronary intervention (PCI) and fibrinolytic therapy, respectively. Seventy-five percent of patients underwent in-hospital PCI (elective, rescue, and primary). At 10 years, 42% of patients suffered a RICE, with most RICEs (88%) caused by recurrent cardiac ischemia. The risk of RICE was the highest during the first year (23.5 per patient-year). At 10 years, the all-cause mortality was 19.3%, with 1/3 of deaths being RICE-related. Previous cardiovascular event, heart failure during the index STEMI hospitalization, discharge prescription of calcium blocker increased the risk of RICE by almost twofold. Each point increase in TIMI (Thrombolysis In Myocardial Infarction) score augmented the risk of RICE by 6%, whereas discharge prescription of dual antiplatelets reduced the risk of RICE by 23%. Our findings suggested that survivors of STEMI remain at high long-term risk of RICE despite high rate of reperfusion therapy and in-hospital PCI. Patients with previous cardiovascular event, in-hospital heart failure, and high TIMI score were particularly susceptible to RICE. Future studies are needed to confirm the impacts of calcium blocker and dual antiplatelets on long-term risk of RICE.


Subject(s)
Calcium Channel Blockers/therapeutic use , Heart Failure/epidemiology , Myocardial Ischemia/epidemiology , Percutaneous Coronary Intervention , Platelet Aggregation Inhibitors/therapeutic use , ST Elevation Myocardial Infarction/therapy , Thrombolytic Therapy , Acute Coronary Syndrome/epidemiology , Acute Coronary Syndrome/mortality , Aged , Angina Pectoris/epidemiology , Angina Pectoris/mortality , Carotid Stenosis/epidemiology , Carotid Stenosis/mortality , Cause of Death , Coronary Artery Disease/epidemiology , Coronary Artery Disease/mortality , Drug Therapy, Combination , Female , Heart Aneurysm/epidemiology , Heart Aneurysm/mortality , Humans , Ischemic Attack, Transient/epidemiology , Ischemic Attack, Transient/mortality , Male , Middle Aged , Mortality , Myocardial Infarction/epidemiology , Myocardial Infarction/mortality , Myocardial Ischemia/mortality , Peripheral Arterial Disease/epidemiology , Peripheral Arterial Disease/mortality , Protective Factors , Quebec/epidemiology , Recurrence , Risk Factors , ST Elevation Myocardial Infarction/epidemiology , Stroke/epidemiology , Stroke/mortality , Survivors
SELECTION OF CITATIONS
SEARCH DETAIL
...